Nestle partners with DBV Technologies to develop diagnostic test for cow’s milk

Nestle partners with DBV Technologies

Approx. 5 to 15% newborn children show unfavorable responses to proteins present in cow’s milk according to Bloomberg. Milk allergy is one of the most common allergies and one of the top 8 allergy triggers that may lead to life-threatening allergic reactions in some children. The numbers are growing at an alarming rate. Nestle, the world’s largest food company has blown its own trumpet by collaborating with DBV Technologies SA, for the initial right to sell an experimental test to diagnose milk allergy in children. Nestle aims to make out approx. $10 billion business out of its health science unit. DBV Technologies laid down its foundation in 2002 by a pediatric gastroenterologist, with selling testing kit in French pharmacies 12 years back. In a statement by DBV, Nestle preferably can sell globally pending approval. DBV Technologies to develop a diagnostic test for cow’s milk protein(CMP) allergy dubbed “MAG1C” based on the firm’s Viaskin platform.

CMPA, Cow’s Milk Protein diagnosis is difficult and basically involves expensive tests. The increase in milk allergy infants is a cause of concern for parents. Nestle has taken into account the major concern and heading in the same direction to release the stress of parents. By getting the commercial rights to a diagnostic test for CMPA, the world’s largest growing company Nestle can be benefitted. Also, DBV technologies is working on the same Viaskin platform of Epicutaneous Immunotherapy (EPIT) for egg, milk, peanut allergy.

*Source of this article is from:

Leave a Reply

Your email address will not be published. Required fields are marked *